Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Protein Effect||no effect|
|Gene Variant Descriptions||Wild-type PTEN indicates that no mutation has been detected within the PTEN gene.|
|Associated Drug Resistance|
|Category Variants Paths|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PTEN wild-type||glioblastoma||sensitive||2-Methoxyestradiol||Preclinical||Actionable||In a preclinical study, 2-Methoxyestradiol (2ME2) inhibited tumor-induced angiogenesis and reduced tumor growth in PTEN reconstituted GBM cell lines and mouse models (PMID: 24162827).||24162827|
|PTEN wild-type||melanoma||sensitive||E6201||Preclinical||Actionable||In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and sensitivity was associated with wild-type PTEN (PMID: 23039341).||23039341|
|PTEN wild-type||uterine cancer||decreased response||GSK2256098||Preclinical||Actionable||In a preclinical study, GSK2256098 treatment resulted in a decreased response in uterine cancer cells with PTEN wild-type versus uterine cancer cells harboring a PTEN mutation (PMID: 25833835).||25833835|
|PTEN wild-type||ovarian mucinous neoplasm||sensitive||KX2-391||Preclinical||Actionable||In a preclinical study, KX2-391 inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).||24100628|
|PTEN wild-type||ovarian mucinous neoplasm||sensitive||KX2-391 + Oxaliplatin||Preclinical||Actionable||In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) synergistically inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).||24100628|